Logotipo del repositorio
Logotipo del repositorio
 

Lipoproteína (a) LP(a) como posible factor de riesgo cardiovascular en pacientes mayores de 40 años en un centro de salud de la ciudad de Barranquilla, Colombia

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_f1cf
dc.contributor.advisorUrina Triana, Miguel
dc.contributor.advisorUrina Triana, Manuel
dc.contributor.authorCampos Del valle, Carlos
dc.date.accessioned2025-02-03T21:18:33Z
dc.date.available2025-02-03T21:18:33Z
dc.date.issued2025
dc.description.abstractAntecedentes: La lipoproteína a [Lp(a)], es una variante estructural de la lipoproteína de baja densidad (LDL) caracterizada por la presencia de apolipoproteína(a) en su estructura. Estudios recientes han asociado niveles sanguíneos elevados (>50 mg/dL) de Lp(a) con un mayor riesgo de eventos cardiovasculares, dado el rol que posee en procesos proaterogénicos, inflamatorios y trombogénicos. En este sentido, su síntesis se caracteriza por poseer una fuerte influencia genotípica, describiendo una susceptibilidad relativamente baja frente a terapias convencionales como las mediadas por estatinas. Objetivo: En el presente trabajo se evalúa el papel de los niveles de Lp(a) en sangre como posible factor predictivo en la reclasificación del riesgo y en el desarrollo de enfermedades cardiovasculares en pacientes mayores de 40 años con y sin historial clínico de eventos cardiovasculares. Metodología: Estudio retrospectivo de corte transversal basado en la revisión de una base de datos de pacientes de consulta externa, consolidada del centro de atención cardiovascular Cardiodiagnóstico S.A. mediante la herramienta SALUD TOOLS, en la ciudad de Barranquilla, Colombia. Se seleccionó una muestra de n=62 pacientes mayores de 40 años que incluye hombres y mujeres, independientemente de la presencia de comorbilidades o antecedentes cardiovasculares, siempre que cumplan con los criterios de inclusión que comprenden a pacientes con registros completos de sus niveles de lipoproteína (a), así como los datos necesarios para calcular el riesgo cardiovascular mediante la escala ASCVD, focalizando en el estrato muestral de pacientes mayores de 40 años, ya que representan individuos para los cuales es aplicable la estimación del riesgo de ECV mediante ASCVD. Resultados: Se espera determinar si la lipoproteína a incide en la reclasificación del riesgo cardiovascular, así como su posible influencia particular en la ocurrencia de eventos cardiovasculares en los pacientes con riesgo moderado y riesgo alto.spa
dc.description.abstractBackground: Lipoprotein(a) [Lp(a)] is a structural variant of low-density lipoprotein (LDL), characterized by the presence of apolipoprotein(a) in its structure. Recent studies have linked elevated blood levels (>50 mg/dL) of Lp(a) with a higher risk of cardiovascular events, given its role in pro-atherogenic, inflammatory, and thrombogenic processes. Its synthesis is strongly influenced by genetic factors, showing relatively low susceptibility to conventional therapies, such as statin-based treatments. Objective: This study evaluates the role of blood Lp(a) levels as a potential predictive factor in risk reclassification and the development of cardiovascular diseases in patients aged over 40, with and without a history of cardiovascular events. Methodology: A retrospective cross-sectional cohort study was conducted based on the review of an outpatient database from the cardiovascular care center Cardiodiagnóstico S.A. in Barranquilla, Colombia, using the SALUD TOOLS platform. A sample of n=62 patients over 40 years of age was selected, including men and women, regardless of comorbidities or cardiovascular history, provided they met the inclusion criteria. These criteria required complete records of their lipoprotein(a) levels and sufficient data to calculate cardiovascular risk using the ASCVD scale. The study focuses on the subset of patients over 40 years old, as they represent individuals for whom ASCVD-based cardiovascular risk estimation is applicable. Results: The study aims to determine whether lipoprotein(a) contributes to cardiovascular risk reclassification and assess its potential influence on the occurrence of cardiovascular events, particularly in patients with moderate and high risk.eng
dc.format.mimetypepdf
dc.identifier.urihttps://hdl.handle.net/20.500.12442/16197
dc.language.isospa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United Stateseng
dc.rights.accessrightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.subjectLipoproteína aspa
dc.subjectRiesgo cardiovascularspa
dc.subjectEventos cardiovascularesspa
dc.subjectAteroesclerosisspa
dc.subject.keywordsLipoprotein(a)eng
dc.subject.keywordsCardiovascular riskeng
dc.subject.keywordsCardiovascular eventseng
dc.subject.keywordsAtherosclerosiseng
dc.titleLipoproteína (a) LP(a) como posible factor de riesgo cardiovascular en pacientes mayores de 40 años en un centro de salud de la ciudad de Barranquilla, Colombiaspa
dc.type.driverinfo:eu-repo/semantics/other
dc.type.spaOtros
dcterms.referencesTsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, Tardif JC, Baum SJ, Steinhagen-Thiessen E, et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease [Internet]. Vol. 382, New England Journal of Medicine. Massachusetts Medical Society; 2020. p. 244–55. DOI:10.1056/NEJMoa1905239eng
dcterms.referencesBergmark C, Dewan A, Orsoni A, Merki E, Miller ER, Shin MJ, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49(10):2230-9. doi:10.1194/jlr.M800174-JLR200.eng
dcterms.referencesNordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844-53. doi:10.1093/eurheartj/ehq386.eng
dcterms.referencesKronenberg F. Human genetics and the causal role of lipoprotein(a) for various diseases. Cardiovasc Drugs Ther. 2016;30(1):87-100. doi:10.1007/s10557-016-6648-3.eng
dcterms.referencesClarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518-28. doi:10.1056/NEJMoa0902604.eng
dcterms.referencesErqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, et al.Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412-23. doi:10.1001/jama.2009.1063.eng
dcterms.referencesReyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association [Internet]. Vol. 42, Arteriosclerosis, Thrombosis, and Vascular Biology. Ovid Technologies (Wolters Kluwer Health); 2022. Available from: DOI:10.1161/ATV.0000000000000147eng
dcterms.referencesMack S, Coassin S, Rueedi R, Yousri NA, Seppälä I, Gieger C, et al. A genome-wide association meta-analysis on lipoprotein(a) concentrations adjusted for apolipoprotein(a) isoforms. J Lipid Res. DOI: 10.1194/jlr.M076232eng
dcterms.referencesMillán, Jesús, et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vascular health and risk management (2009): 757-765. PMID: 19774217eng
dcterms.referencesBjörnson E, Adiels M, Taskinen M-R, Burgess S, Chapman MJ, Packard CJ, et al. Lipoprotein(a) is markedly more atherogenic than LDL: An apolipoprotein B-based genetic analysis. J Am Coll Cardiol [Internet]. 2024;83(3):385–95. Available from: http://dx.doi.org/10.1016/j.jacc.2023.10.039eng
dcterms.referencesThanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368(6):503-12. doi:10.1056/NEJMoa1109034.eng
dcterms.referencesCapoulade R, Chan KL, Yeang C, Mathieu P, Dumesnil JG, Tam JW, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol. 2015;66(11):1236-46. doi:10.1016/j.jacc.2015.07.020.eng
dcterms.referencesTsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, et al. NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71(2):177-92. doi:10.1016/j.jacc.2017.11.014.eng
dcterms.referencesPasławska A, Tomasik PJ. Lipoprotein(a)-60 years later-what do we know? Cells [Internet]. 2023;12(20):2472. Available from: http://dx.doi.org/10.3390/cells12202472eng
dcterms.referencesThomas PE, Vedel-Krogh S, Nordestgaard BG. Lipoprotein(a) in cardiovascular disease: Evidence from large epidemiological studies. In: Contemporary Cardiology. Cham: Springer International Publishing; 2023. p. 251–9. https://doi.org/10.1007/978-3-031-24575-6_15eng
dcterms.referencesZheng KH, Tsimikas S, Pawade T, Kroon J, Jenkins WSA, Doris MK, et al. Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis. J Am Coll Cardiol [Internet]. 2019;73(17):2150–62. Available from: http://dx.doi.org/10.1016/j.jacc.2019.01.070eng
dcterms.referencesHandhle A, Viljoen A, Wierzbicki AS. Elevated lipoprotein(a): Background, current insights and future potential therapies. Vasc Health Risk Manag [Internet]. 2021;17:527–42. Available from: http://dx.doi.org/10.2147/VHRM.S266244eng
dcterms.referencesCarpenito T, Manjourides J. MISL: Multiple imputation by super learning. Stat Methods Med Res [Internet]. 2022;31(10):1904–15. Available from: http://dx.doi.org/10.1177/09622802221104238eng
dcterms.referencesWilcox RR, Tian TS. Measuring effect size: a robust heteroscedastic approach for two or more groups. Vol. 38, Journal of Applied Statistics. Informa UK Limited; 2011. p. 1359–68. Available from: http://dx.doi.org/10.1080/02664763.2010.498507eng
dcterms.referencesWilcox, Rand R. Introduction to Robust Estimation and Hypothesis Testing. Elsevier; 2012. Available from: http://dx.doi.org/10.1016/C2010-0-67044-1eng
dcterms.referencesNguelifack BM, Kemajou-Brown I. Robust rank-based variable selection in double generalized linear models with diverging number of parameters under adaptive Lasso. J Stat Comput Simul [Internet]. 2019;89(11):2051–72. Available from: http://dx.doi.org/10.1080/00949655.2019.1607346eng
dcterms.referencesWang L, Li J, Liu J, Chang M. RAMRSGL: A Robust Adaptive Multinomial Regression Model for Multicancer Classification [Internet]. Chen L, editor. Vol. 2021, Computational and Mathematical Methods in Medicine. Hindawi Limited; 2021. p. 1–13. Available from: http://dx.doi.org/10.1155/2021/5584684eng
dcterms.referencesAgrawal A, Viktor HL, Paquet E. SCUT: Multi-class imbalanced data classification using SMOTE and cluster-based undersampling. In: Proceedings of the 7th International Joint Conference on Knowledge Discovery, Knowledge Engineering and Knowledge Management. SCITEPRESS - Science and and Technology Publications; 2015.eng
dcterms.referencesFan, S., Zhao, Z., Yu, H. et al. Applying probability calibration to ensemble methods to predict 2-year mortality in patients with DLBCL. BMC Med Inform Decis Mak 21, 14 (2021). https://doi.org/10.1186/s12911-020-01354-0eng
dcterms.referencesLundberg S, Lee S-I. A unified approach to interpreting model predictions [Internet]. arXiv [cs.AI]. 2017. Available from: http://arxiv.org/abs/1705.07874eng
dcterms.referencesYu W, Yang L, Zhang F, Liu B, Shi Y, Wang J, et al. Machine learning to predict hemodynamically significant CAD based on traditional risk factors, coronary artery calcium and epicardial fat volume. J Nucl Cardiol [Internet]. 2023;30(6):2593–606. Available from: http://dx.doi.org/10.1007/s12350-023-03333-0eng
dcterms.referencesRuixing Y, Hui L, Jinzhen W, Weixiong L, Dezhai Y, Shangling P, et al. Association of diet and lifestyle with blood pressure in the Guangxi Hei Yi Zhuang and Han populations [Internet]. Vol. 12, Public Health Nutrition. Cambridge University Press (CUP); 2008. p. 553. Available from: http://dx.doi.org/10.1017/S1368980008002437eng
dcterms.referencesTani S, Matsuo R, Imatake K, Suzuki Y, Takahashi A, Matsumoto N. Association of daily fish intake with serum non-high-density lipoprotein cholesterol levels and healthy lifestyle behaviours in apparently healthy males over the age of 50 years in Japanese: Implication for the anti-atherosclerotic effect of fish consumption [Internet]. Vol. 30, Nutrition, Metabolism and Cardiovascular Diseases. Elsevier BV; 2020. p. 190–200. Available from: http://dx.doi.org/10.1016/j.numecd.2019.09.019eng
dcterms.referencesSuk Danik J, Chasman DI, Cannon CP, Miller DT, Zee RYL, Kozlowski P, et al. Influence of Genetic Variation in the C‐Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia [Internet]. Vol. 70, Annals of Human Genetics. Wiley; 2006. p. 705–16. Available from: http://dx.doi.org/10.1111/j.1469-1809.2006.00272.xeng
dcterms.referencesSong JJ, Ma Z, Wang J, Chen LX, Zhong JC. Gender Differences in Hypertension [Internet]. Vol. 13, Journal of Cardiovascular Translational Research. Springer Science and Business Media LLC; 2019. p. 47–54. Available from: http://dx.doi.org/10.1007/s12265-019-09888-zeng
dcterms.referencesPradhan AD, Rifai N, Buring JE, Ridker PM. Hemoglobin A1c Predicts Diabetes but Not Cardiovascular Disease in Nondiabetic Women [Internet]. Vol. 120, The American Journal of Medicine. Elsevier BV; 2007. p. 720–7. Available from: http://dx.doi.org/10.1016/j.amjmed.2007.03.022eng
dcterms.referencesPalmisano BT, Zhu L, Eckel RH, Stafford JM. Sex differences in lipid and lipoprotein metabolism [Internet]. Vol. 15, Molecular Metabolism. Elsevier BV; 2018. p. 45–55. Available from: http://dx.doi.org/10.1016/j.molmet.2018.05.008eng
dcterms.referencesBerglund L, Ramakrishnan R. Lipoprotein(a) [Internet]. Vol. 24, Arteriosclerosis, Thrombosis, and Vascular Biology. Ovid Technologies (Wolters Kluwer Health); 2004. p. 2219–26. Available from: http://dx.doi.org/10.1161/01.ATV.0000144010.55563.63eng
dcterms.referencesEnkhmaa B, Anuurad E, Berglund L. Lipoprotein (a): impact by ethnicity and environmental and medical conditions [Internet]. Vol. 57, Journal of Lipid Research. Elsevier BV; 2016. p. 1111–25. Available from: http://dx.doi.org/10.1194/jlr.R051904eng
dcterms.referencesHopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR. Lipoprotein(a) Interactions With Lipid and Nonlipid Risk Factors in Early Familial Coronary Artery Disease [Internet]. Vol. 17, Arteriosclerosis, Thrombosis, and Vascular Biology. Ovid Technologies (Wolters Kluwer Health); 1997. p. 2783–92. Available from: http://dx.doi.org/10.1161/01.ATV.17.11.2783eng
dcterms.referencesEnkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations [Internet]. Vol. 349, Atherosclerosis. Elsevier BV; 2022. p. 53–62. Available from: http://dx.doi.org/10.1016/j.atherosclerosis.2022.04.006eng
dcterms.referencesSun P, Dwyer KM, Merz CNB, Sun W, Johnson CA, Shircore AM, et al. Blood Pressure, LDL Cholesterol, and Intima-Media Thickness [Internet]. Vol. 20, Arteriosclerosis, Thrombosis, and Vascular Biology. Ovid Technologies (Wolters Kluwer Health); 2000. p. 2005–10. Available from: http://dx.doi.org/10.1161/01.ATV.20.8.2005eng
dcterms.referencesYu XH, Zhang DW, Zheng XL, Tang CK. Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis [Internet]. Vol. 73, Progress in Lipid Research. Elsevier BV; 2019. p. 65–91. Available from: http://dx.doi.org/10.1016/j.plipres.2018.12.002eng
dcterms.referencesWhite RE, Gerrity R, Barman SA, Han G. Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women [Internet]. Vol. 75, Steroids. Elsevier BV; 2010. p. 788–93. Available from: http://dx.doi.org/10.1016/j.steroids.2009.12.007eng
dcterms.referencesSimonetto C, Rospleszcz S, Kaiser JC, Furukawa K. Heterogeneity in coronary heart disease risk [Internet]. Vol. 12, Scientific Reports. Springer Science and Business Media LLC; 2022. Available from: http://dx.doi.org/10.1038/s41598-022-14013-3eng
dcterms.referencesAgarwala A, Liu J, Ballantyne CM, Virani SS. The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines [Internet]. Vol. 13, Current Cardiovascular Risk Reports. Springer Science and Business Media LLC; 2019. Available from: http://dx.doi.org/10.1007/s12170-019-0616-yeng
dcterms.referencesKannel WB. Elevated systolic blood pressure as a cardiovascular risk factor [Internet]. Vol. 85, The American Journal of Cardiology. Elsevier BV; 2000. p. 251–5. Available from: http://dx.doi.org/10.1016/S0002-9149(99)00635-9eng
dcterms.referencesSuman S, Pravalika J, Manjula P, Farooq U. Gender and CVD- Does It Really Matters? [Internet]. Vol. 48, Current Problems in Cardiology. Elsevier BV; 2023. p. 101604. Available from: http://dx.doi.org/10.1016/j.cpcardiol.2023.101604eng
dcterms.referencesMudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, et al. Beyond Low-Density Lipoprotein Cholesterol [Internet]. Vol. 50, Journal of the American College of Cardiology. Elsevier BV; 2007. p. 1735–41. Available from: http://dx.doi.org/10.1016/j.jacc.2007.07.045eng
dcterms.referencesLanglois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM [Internet]. Vol. 64, Clinical Chemistry. Oxford University Press (OUP); 2018. p. 1006–33. Available from: http://dx.doi.org/10.1373/clinchem.2018.287037eng
dcterms.referencesPastor-Barriuso, Roberto, et al. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Annals of internal medicine 139.9 (2003): 731-739.eng
oaire.versioninfo:eu-repo/semantics/acceptedVersion
sb.programaEspecialización en Cardiologíaspa
sb.sedeSede Barranquillaspa

Archivos

Bloque original
Mostrando 1 - 2 de 2
Miniatura
Nombre:
PDF_Resumen.pdf
Tamaño:
251.74 KB
Formato:
Adobe Portable Document Format
Descargar
No hay miniatura disponible
Nombre:
PDF.pdf
Tamaño:
875.15 KB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
2.93 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Especialización

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca